SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

That’s according to a clinical trial conducted in 11 countries — the first of its kind to show that one of the wave of ...

Popular GLP-1 drugs are already known to have many benefits, but scientists continue to explore what else they — and their ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

A new study examining a large sample of privately insured patients with obesity found that use of drugs such as Ozempic and Wegovy as anti-obesity medications more than doubled from 2022 to 2023.

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales. Viking's ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications.

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical ...

Obesity treatment shifts from surgery to drugs as bariatric procedures decline by 25.6% and GLP-1 receptor agonist use jumps ...